385 related articles for article (PubMed ID: 1726206)
21. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia.
Zuck P; Rio Y; Ichou F
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():71-7. PubMed ID: 2292534
[TBL] [Abstract][Full Text] [Related]
22. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
Zeckel ML; Jacobson KD; Guerra FJ; Therasse DG; Farlow D
Clin Ther; 1992; 14(2):214-29. PubMed ID: 1611645
[TBL] [Abstract][Full Text] [Related]
23. [RU 51807 (cefpodoxime proxetil). In vitro and in vivo antibacterial activity of a new orally administered active cephalosporin].
Chantot JF; Mauvais P
Pathol Biol (Paris); 1991 Jan; 39(1):17-27. PubMed ID: 1901403
[TBL] [Abstract][Full Text] [Related]
24. [Clinical evaluation of cefpodoxime proxetil, a new oral cephem, in the treatment of respiratory tract infections with the special reference to community-acquired Streptococcus Pneumoniae infections].
Akiyama O; Ito T; Ogata M; Okano H; Kabe J; Kawakami M; Kida K; Kudo K; Komatsuzaki K; Konno K
Jpn J Antibiot; 1995 Apr; 48(4):522-8. PubMed ID: 7783315
[TBL] [Abstract][Full Text] [Related]
25. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract.
Doern GV
Am J Med; 1995 Dec; 99(6B):3S-7S. PubMed ID: 8585554
[TBL] [Abstract][Full Text] [Related]
26. [Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field].
Kimura H; Takeuchi H; Ishikawa H; Hayakawa F; Yamamoto N; Nakao Y; Kuno K
Jpn J Antibiot; 1989 Jul; 42(7):1593-606. PubMed ID: 2562789
[TBL] [Abstract][Full Text] [Related]
27. Respiratory tract infection: epidemiology and surveillance.
Jacobs MR
J Chemother; 1997 May; 9 Suppl 3():10-7. PubMed ID: 9248976
[TBL] [Abstract][Full Text] [Related]
28. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.
Stevens DL; Pien F; Drehobl M
Diagn Microbiol Infect Dis; 1993 Feb; 16(2):123-9. PubMed ID: 8467623
[TBL] [Abstract][Full Text] [Related]
29. A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.
Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
J Chemother; 2000 Jun; 12(3):223-7. PubMed ID: 10877517
[TBL] [Abstract][Full Text] [Related]
30. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
Wallrauch-Schwarz C; Milatovic D; Braveny I
Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerance of erythromycin acistrate in the treatment of acute exacerbations of chronic bronchitis in the elderly.
Forsén KO; Wikberg R; Lehtonen L
Chemotherapy; 1993; 39(6):443-52. PubMed ID: 8222874
[TBL] [Abstract][Full Text] [Related]
32. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.
Dere WH; Farlow D; Therasse DG; Jacobson KD; Guerra FJ
Clin Ther; 1992; 14(2):166-77. PubMed ID: 1611641
[TBL] [Abstract][Full Text] [Related]
33. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
Perry CM; Scott LJ
Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
[TBL] [Abstract][Full Text] [Related]
34. Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin.
Chocas EC; Paap CM; Godley PJ
Ann Pharmacother; 1993 Nov; 27(11):1369-77. PubMed ID: 8286813
[TBL] [Abstract][Full Text] [Related]
35. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
DeAbate CA; Henry D; Bensch G; Jubran A; Chodosh S; Harper L; Tipping D; Talbot GH
Chest; 1998 Jul; 114(1):120-30. PubMed ID: 9674458
[TBL] [Abstract][Full Text] [Related]
36. Cefpodoxime proxetil in the treatment of skin and soft tissue infections.
Tack KJ; Wilks NE; Semerdjian G; Frazier CH; Shirin K; Puopolo A; Crossland SG; Goffe BS; Millikan L
Drugs; 1991; 42 Suppl 3():51-6. PubMed ID: 1726208
[TBL] [Abstract][Full Text] [Related]
37. [Respiratory tract infections in general practice. Cefpodoxime proxetil in patients with risk factors and concomitant illnesses].
Kardos P; Wiese K
MMW Fortschr Med; 2000 Feb; 142(5):41. PubMed ID: 10715939
[No Abstract] [Full Text] [Related]
38. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis.
Cazzola M; Di Perna F; Boveri B; Di Marco F; Diamare F; Centanni S
J Chemother; 2000 Jun; 12(3):216-22. PubMed ID: 10877516
[TBL] [Abstract][Full Text] [Related]
39. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens--findings of the Alexander Project 1992-1996.
Felmingham D; Washington J
J Chemother; 1999 Feb; 11 Suppl 1():5-21. PubMed ID: 10207769
[TBL] [Abstract][Full Text] [Related]
40. Antibiotic resistance. Epidemiology of resistance--respiratory tract infections.
Thomson CJ
J Med Microbiol; 1997 Jun; 46(6):442-5. PubMed ID: 9379469
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
